Surgical resection is highly effective for UCD with a 95% 10-year overall survival rate.[10] B cell depletion with rituximab induces durable remission in nearly all HHV-8-associated MCD cases, leading to a 92% 5-year overall survival.[11] The anti-IL-6 therapy, siltuximab, is effective in about one-third of iMCD patients and considered front-line treatment. This evidence concerns the gene IL6 and urea cycle disorder.